Eli Aharoni
Directeur Technique/Scientifique/R&D chez SAMSARA VISION, INC.
Profil
Eli Aharoni is currently working as Vice President-Research & Development, GM at Samsara Vision, Inc. He previously worked as Vice President-Finance at Acceleron Pharma, Inc. He completed his undergraduate degree from Technion-Israel Institute of Technology.
Postes actifs de Eli Aharoni
| Sociétés | Poste | Début |
|---|---|---|
| SAMSARA VISION, INC. | Directeur Technique/Scientifique/R&D | 01/01/2001 |
Anciens postes connus de Eli Aharoni
| Sociétés | Poste | Fin |
|---|---|---|
| ACCELERON PHARMA INC. | Directeur Financier/CFO | - |
Formation de Eli Aharoni
| Technion-Israel Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Samsara Vision, Inc.
 Samsara Vision, Inc. Medical SpecialtiesHealth Technology Samsara Vision, Inc. engages in the business of research, development, manufacturing, and marketing proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. It operates under the United States and Other geographical segments. The company was founded by Isaac Lipshitz, David Lifschitz, Yossi Gross, Boaz Lifschitz, and Eyal Lifschitz in 1997 and is headquartered in Far Hills, NJ. | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |